Floatz logo

Urea

Inappropriate ADH Syndrome

Helbert Rondon Berrios, MD, MSSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Inappropriate ADH Syndrome cohort.

Asset / SponsorPhaseRating
Tolvaptan
King's College Hospital NHS Trust
Phase 3BBB
Empagliflozin
University Hospital, Basel, Switzerland
Phase 4BB
SATAVAPTAN MONOPHOSPHATE
Sanofi
Phase 3BB
Lixivaptan
CardioKine Inc.
Phase 3BB
Satavaptan
Sanofi
Phase 3B

Same molecule, other indications

Urea is also rated in:

radiodermatitisDormant
BB
Indicative ·
69 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
63 / 100
View asset →
cancer of unknown primary siteDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →